Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12;57(11):2688-2703.e11.
doi: 10.1016/j.immuni.2024.09.003. Epub 2024 Oct 4.

T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels

Affiliations

T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels

Julia M Messmer et al. Immunity. .

Abstract

To improve immunotherapy for brain tumors, it is important to determine the principal intracranial site of T cell recruitment from the bloodstream and their intracranial route to brain tumors. Using intravital microscopy in mouse models of intracranial melanoma, we discovered that circulating T cells preferably adhered and extravasated at a distinct type of venous blood vessel in the tumor vicinity, peritumoral venous vessels (PVVs). Other vascular structures were excluded as alternative T cell routes to intracranial melanomas. Anti-PD-1/CTLA-4 immune checkpoint inhibitors increased intracranial T cell motility, facilitating migration from PVVs to the tumor and subsequently inhibiting intracranial tumor growth. The endothelial adhesion molecule ICAM-1 was particularly expressed on PVVs, and, in samples of human brain metastases, ICAM-1 positivity of PVV-like vessels correlated with intratumoral T cell infiltration. These findings uncover a distinct mechanism by which the immune system can access and control brain tumors and potentially influence other brain pathologies.

Keywords: brain cancer; brain metastases; brain metastasis; cancer; immunotherapy; intravital imaging; lymphocyte recruitment; melanoma; tumor immunology.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests F.W. reports receiving research grants from Boehringer, Genentech, Roche, and Divide and Conquer Ltd.

Comment in

References

Publication types

Substances